- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
New treatment strategy for down syndrome shows promise in phase 2 clinical trial

In a first-of-its-kind clinical trial, researchers at the Linda Crnic Institute for Down Syndrome (Crnic Institute) at the University of Colorado Anschutz found that a medication targeting immune overactivity in people with Down syndrome reduced underlying inflammation and was associated with improvements in inflammatory skin conditions, while opening new avenues for research on brain health and Alzheimer’s disease.
The phase 2 clinical trial of tofacitinib, a medication known as a JAK inhibitor that blocks certain signals involved in immune responses and inflammation, was published today in Cell Reports Medicine.
The findings provide important evidence that targeting underlying immune dysregulation may offer a new approach to addressing multiple health conditions associated with Down syndrome.
Why researchers targeted immune hyperactivity in Down syndrome
Down syndrome is caused by an extra copy of chromosome 21, which carries genes encoding several receptors for interferons, molecules that regulate immune responses. Previous research by the Crnic Institute established that this genetic change contributes to chronically elevated interferon signaling and widespread immune dysregulation. The new study tested whether reducing this excessive signaling could be a viable therapeutic approach.
How the phase 2 clinical trial for JAK inhibition worked
The research team enrolled adolescents and adults with Down syndrome who also had inflammatory skin conditions, such as hidradenitis suppurativa and alopecia areata. Participants received tofacitinib twice daily for 16 weeks, with an optional extension to 40 weeks. The trial included extensive safety monitoring, dermatological evaluations, blood-based molecular analyses and neuropsychological assessments. The study also evaluated changes in biological markers associated with brain health and Alzheimer's disease.
“This study represents an important milestone in our efforts to develop new treatments for people with Down syndrome,” said Joaquín Espinosa, PhD, executive director of the Crnic Institute, professor of pharmacology, and senior author of the study. “We have demonstrated that we can reduce excessive immune activity and improve certain inflammatory conditions. The results of this study lay the groundwork for future clinical trials that could address a broader range of conditions associated with Down syndrome.”
Study finds reduced inflammation and improvements in skin conditions
The study met its predefined safety endpoint, with a safety profile similar to that observed in the general population. The findings do not eliminate the known risks of JAK inhibitors and larger studies will be needed to assess long-term safety in Down syndrome.
Blood analyses showed significant reductions in interferon activity, inflammatory cytokine scores and metabolites associated with inflammation, including quinolinic acid, a compound with known neurotoxic effects. Extensive analyses of gene expression, circulating proteins, and metabolites showed that tofacitinib modified specific inflammatory pathways rather than completely shutting down immune responses.
“One of the most exciting findings is that we could bring several abnormal inflammatory markers closer to the levels observed in people without Down syndrome,” said Angela Rachubinski, PhD, first author of the study. “Importantly, this medication appears to calm an overactive immune system without weakening normal immune defenses in people with Down syndrome, which may explain its encouraging safety profile.”
Participants also showed improvements in inflammatory skin conditions, particularly hidradenitis suppurativa, which causes painful skin lesions, and alopecia areata, an autoimmune condition that causes hair loss. Improvements were documented through standardized clinical scores and measures of dermatology-related quality of life.
Neurobehavioral findings are promising but preliminary
The investigators additionally observed improved performance on selected tests of attention, memory, vocabulary and behaviors, along with favorable changes in some participant- and caregiver-reported measures of well-being. These findings are preliminary: because the study had no placebo comparison group, researchers cannot determine whether the observed changes were caused by tofacitinib rather than practice effects or other factors.
“The neuropsychological results are intriguing, but they are not yet proof that this medicine improves cognition,” said Lina Patel, PsyD, a study coauthor and professor of psychiatry at CU Anschutz. “What this study establishes is an opportunity to ask more precise questions about which improvements may be due to treatment, while continuing to prioritize participant safety.”
These findings may help advance research into how chronic immune overactivity affects the brain and whether targeting inflammation could improve brain health in people with Down syndrome. Researchers documented favorable changes in several biomarkers related to neurological function and Alzheimer’s disease, opening new avenues of future research.
Based on the results from this first trial, researchers launched a second trial focused on Down Syndrome Regression Disorder, a condition characterized by sudden loss of neurological function that has been associated with inflammatory processes affecting the brain. Results from this second trial are expected to be available in 2027.
The research builds on the Crnic Institute’s Human Trisome Project, which has mapped immune and molecular changes associated with Down syndrome. By comparing trial findings with those earlier datasets, the team identified biological changes that may be responsive to JAK inhibition and biomarkers for monitoring treatment effects.
“As the mother of my amazing 23-year-old daughter Sophia, it is deeply moving to see the Crnic Institute's groundbreaking research, which GLOBAL supported from the beginning, lead to promising clinical results,” said Michelle Sie Whitten, president and CEO of the Global Down Syndrome Foundation. “We are grateful to the NIH INCLUDE Project and to Dr. Joaquín Espinosa and his team for focusing on scientific discoveries leading to longer, healthier lives.”
What the findings mean for future Down syndrome treatments
The authors emphasize that tofacitinib is not approved specifically for Down syndrome and that the study does not establish a general treatment recommendation. The findings support further randomized, placebo-controlled studies to evaluate clinical benefits, optimal participant selection and longer-term safety.
The study, “A phase 2, open-label, single-arm clinical trial of the safety and efficacy of the JAK1/3 inhibitor tofacitinib in Down syndrome,” is registered as NCT04246372 (https://clinicaltrials.gov/study/NCT04246372). Funding included the NIH INCLUDE Project, the Global Down Syndrome Foundation, the Anna and John J. Sie Foundation and the Ruth E. Olleman Trust.
The takeaway: Researchers at the Linda Crnic Institute for Down Syndrome at the University of Colorado Anschutz found that tofacitinib, a medication that targets an overactive immune signaling pathway, reduced inflammation and improved certain inflammatory skin conditions in adolescents and adults with Down syndrome. The phase 2 clinical trial, published in Cell Reports Medicine, also identified preliminary improvements on selected neurobehavioral assessments, although larger, placebo-controlled studies are needed to determine whether the medication improves neurological function.
Key Points
- Researchers at the Linda Crnic Institute for Down Syndrome at the University of Colorado Anschutz tested tofacitinib, a JAK inhibitor, in adolescents and adults with Down syndrome.
- The phase 2 clinical trial found reductions in overactive interferon signaling and other markers of inflammation.
- Participants experienced improvements in certain inflammatory skin conditions, including hidradenitis suppurativa and alopecia areata.
- Exploratory neurobehavioral assessments showed encouraging changes, but the study cannot establish that tofacitinib caused these improvements.
- Tofacitinib is not approved specifically for Down syndrome. Larger, randomized clinical trials are needed to evaluate effectiveness and long-term safety.
Reference:
Rachubinski A, Gurnee E, Wallace E ... A phase 2, open-label, single-arm clinical trial of the safety and efficacy of the JAK1/3 inhibitor tofacitinib in Down syndrome, Cell Reports Medicine, DOI: 10.1016/j.xcrm.2026.103138
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751

